DSGN - Design Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

9.018M

Cash

270.7M

Avg Qtr Burn

-13.39M

Short % of Float

12.54%

Insider Ownership

36.54%

Institutional Own.

54.67%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DT-216 Details Friedreich’s Ataxia	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DT-168 Details Fuchs Endothelial Corneal Dystrophy , Eye disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.